IN8BIO, INC. (INAB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45674E2081
IN8BIO, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -19.44 m USD |
| EBIT | -19.86 m USD |
| Net income | -19.44 m USD |
| Diluted EPS – continuing operations | -4.44 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About IN8BIO, INC.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
More stocks
- BION ENVIRONMENTAL TECHNOLOGIES INC (BNET)
- DIXIE GROUP INC (DXYN)
- Concrete Leveling Systems Inc (CLEV)
- Trio Petroleum Corp (TPET)
- CLEARONE INC (CLRO)
- ASTROTECH Corp (ASTC)
- Aspira Women's Health Inc. (AWHL)
- P3 Health Partners Inc. (PIII)
- Chinhung International Inc. Pfd. Series 2 (002787.KS)
- Sundance Strategies, Inc. (SUND)
- MetaVia Inc. (MTVA)
- LIQTECH INTERNATIONAL INC (LIQT)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.